UB Paderborn / Katalog / Suche / in CDI

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

PloS one, 2018-10, Vol.13 (10), p.e0204973

2018

Link zum Volltext

Verfügbarkeit prüfen

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2762-2772

2020

Link zum Volltext

Verfügbarkeit prüfen

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Journal of clinical oncology, 2022-09, Vol.40 (27), p.JCO2100277-3204

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis

Journal of clinical oncology, 2022-07, Vol.40 (19), p.JCO2101958-2162

2022

Link zum Volltext

Verfügbarkeit prüfen

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

British journal of cancer, 2024-03, Vol.130 (4), p.613-619

2024

Link zum Volltext

Verfügbarkeit prüfen

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity

Drug safety, 2020-10, Vol.43 (10), p.1045-1055

2020

Link zum Volltext

Verfügbarkeit prüfen

Systemic neoadjuvant therapy of luminal breast cancer in 2016

Bulletin du cancer, 2017-01, Vol.104 (1), p.69

Cottu, Paul H

2017

Link zum Volltext

Verfügbarkeit prüfen

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

BMC cancer, 2010-05, Vol.10 (1), p.222-222, Article 222

2010

Link zum Volltext

Verfügbarkeit prüfen

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Journal of neuro-oncology, 2009-07, Vol.93 (3), p.379-384

2009

Link zum Volltext

Verfügbarkeit prüfen

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France

Breast (Edinburgh), 2016-12, Vol.30, p.73-79

2016

Link zum Volltext

Verfügbarkeit prüfen

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines

Cancer research (Chicago, Ill.), 1997-01, Vol.57 (2), p.300-303

1997

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

Journal of clinical oncology, 2010-10, Vol.28 (28), p.e541-e542

2010

Link zum Volltext

Verfügbarkeit prüfen

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy

Anti-cancer drugs, 2011-11, Vol.22 (10), p.1020-1023

2011

Link zum Volltext

Verfügbarkeit prüfen

Les traitements médicaux néoadjuvants des cancers du sein luminaux en 2016

Bulletin du cancer, 2017-01, Vol.104 (1), p.69-78

Cottu, Paul H.

2017

Link zum Volltext

Verfügbarkeit prüfen

Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12110-12110

2020

Link zum Volltext

Verfügbarkeit prüfen

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Journal of neuro-oncology, 2009-07, Vol.93 (3), p.385-385

2009

Link zum Volltext

Verfügbarkeit prüfen

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1064-1064

2021

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience

Bulletin du cancer, 2011-04, Vol.98 (4), p.357

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-27

2022

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13067-e13067

2023

Link zum Volltext

Verfügbarkeit prüfen

Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.546-546

2023

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity

Systemic neoadjuvant therapy of luminal breast cancer in 2016

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy

Les traitements médicaux néoadjuvants des cancers du sein luminaux en 2016

Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program

Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience

Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial

Suchergebnisse filtern